Business
Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that multiple exploratory mechanism-of-action (MoA) analyses of mazdutide (investigator-initiated trials) as well as a preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased at
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, June 21, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that multiple exploratory mechanism-of-action (MoA) analyses of mazdutide (investigator-initiated trials) as well as a preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased at the American Diabetes Association's (ADA) 85th Scientific Sessions. Details are listed below：","length":670,"tagName":"p"},{"type":"text","content":"Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract Number：1886-LBPresentation Form: PosterPresentation Time: Sunday, June 22, 2025. 12:30 P.M. - 1:30 P.M. CDTLocation: Poster Hall (Hall F1)Author: Dr. Decheng Ren, Innovent Biologics","length":330,"tagName":"p"},{"type":"text","content":"IBI3030 is a novel anti-PCSK9 antibody conjugated with peptides targeting GLP-1R, GCGR, and GIPR. Through multi-target synergistic effects, it significantly improves cardiovascular metabolic risk indicators. Mechanistically, the anti-PCSK9 antibody component inhibits LDL receptor degradation, thereby lowering reduce plasma LDL-c levels. Simultaneously, the triple-target agonist peptide activates GLP-1R/GCGR/GIPR receptors, enhancing hepatic fatty acid oxidation capacity, with demonstrates superior efficacy compared to the control. Preclinical studies demonstrate that in multiple models (mice, rats, and non-human primates), IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin sensitivity. Additionally, it exhibits excellent safety in non-human primates, with a maximum tolerated dose reaching 50 mg/kg.","length":1019,"tagName":"p"},{"type":"text","content":"Furthermore, mazdutide, the fastest-developing dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist globally, has ignited significant research interest in the scientific c...